<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><description>BiG，Biologics Innovation Group是由致力于从事生物医药领域研究、开发、应用、临床、投资等工作的独立个人，自愿组织的一个专业/非盈利性机构。正式成立于2014年，迄今会员490余人，相继举办20余场行业峰会。</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 15 Mar 2021 09:50:42 +0800</pubDate><image><url>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</url><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>ADC市场竞逐：荣昌股票翻红，恒瑞、君实加速布局！</title><link>https://mp.weixin.qq.com/s/mZKGkUoq_uGbGPkrTBr8PQ</link><description></description><content:encoded><![CDATA[ADC市场竞逐：荣昌股票翻红，恒瑞、君实加速布局！]]></content:encoded><pubDate>Mon, 15 Mar 2021 07:26:35 +0800</pubDate></item><item><title>SAR-T=CAR-T+双特异性抗体</title><link>https://mp.weixin.qq.com/s/dx5jt0zx2u_bkM1lG416ng</link><description></description><content:encoded><![CDATA[SAR-T=CAR-T+双特异性抗体]]></content:encoded><pubDate>Mon, 15 Mar 2021 07:26:35 +0800</pubDate></item><item><title>ADC迎来修罗场，PDC能否开辟新一春？</title><link>https://mp.weixin.qq.com/s/qQ79X1lZG12UB1MNHc3S2Q</link><description></description><content:encoded><![CDATA[ADC迎来修罗场，PDC能否开辟新一春？]]></content:encoded><pubDate>Fri, 12 Mar 2021 18:32:35 +0800</pubDate></item><item><title>荐 | 60+生物药企领袖聚首申城，研发动态、成果展示、合作案例，你想了解的单抗/双抗/ADC热点尽在BIT 2021！</title><link>https://mp.weixin.qq.com/s/RbbySGCVQjbximU2WBu7fA</link><description></description><content:encoded><![CDATA[荐 | 60+生物药企领袖聚首申城，研发动态、成果展示、合作案例，你想了解的单抗/双抗/ADC热点尽在BIT 2021！]]></content:encoded><pubDate>Fri, 12 Mar 2021 18:32:35 +0800</pubDate></item><item><title>新药上市后商业化有多难？</title><link>https://mp.weixin.qq.com/s/hha7mG2b1al13CN3txBCfw</link><description></description><content:encoded><![CDATA[新药上市后商业化有多难？]]></content:encoded><pubDate>Tue, 09 Mar 2021 22:43:39 +0800</pubDate></item><item><title>百奥赛图CD40抗体申报临床，后PD-1时代新君之争愈加激烈</title><link>https://mp.weixin.qq.com/s/f-sI4TJEun5KUiFhx5eTAw</link><description></description><content:encoded><![CDATA[百奥赛图CD40抗体申报临床，后PD-1时代新君之争愈加激烈]]></content:encoded><pubDate>Mon, 08 Mar 2021 17:11:03 +0800</pubDate></item><item><title>折戟路上的勇士！如何通过临床策略提升ADC成功率？</title><link>https://mp.weixin.qq.com/s/-wibTYu2ciHsWeoP7kE3TQ</link><description></description><content:encoded><![CDATA[折戟路上的勇士！如何通过临床策略提升ADC成功率？]]></content:encoded><pubDate>Fri, 05 Mar 2021 21:35:00 +0800</pubDate></item><item><title>Moderna公布IL-12 mRNA肿瘤疫苗I期数据，联用Durvalumab效果可期</title><link>https://mp.weixin.qq.com/s/-mgaAjHM-rWwM3yhBv6ZOw</link><description></description><content:encoded><![CDATA[Moderna公布IL-12 mRNA肿瘤疫苗I期数据，联用Durvalumab效果可期]]></content:encoded><pubDate>Thu, 04 Mar 2021 18:26:43 +0800</pubDate></item><item><title>免疫单药真的落寞了么，双抗市场究竟蓝海多大？</title><link>https://mp.weixin.qq.com/s/HUjzyzoM77IcpUomM9LIZA</link><description></description><content:encoded><![CDATA[免疫单药真的落寞了么，双抗市场究竟蓝海多大？]]></content:encoded><pubDate>Wed, 03 Mar 2021 17:04:13 +0800</pubDate></item><item><title>缺氧耐药新解法！贝伐珠单抗难治性GBM 2期达到主要终点</title><link>https://mp.weixin.qq.com/s/lWm4o7yj24kobzPJksNxSQ</link><description></description><content:encoded><![CDATA[缺氧耐药新解法！贝伐珠单抗难治性GBM 2期达到主要终点]]></content:encoded><pubDate>Mon, 01 Mar 2021 17:12:48 +0800</pubDate></item><item><title>信达生物新冠抗体项目美国FDA IND获批，苏桥助力2000L GMP生产</title><link>https://mp.weixin.qq.com/s/xTCYtnj4N4VgnqPafbGZYA</link><description></description><content:encoded><![CDATA[信达生物新冠抗体项目美国FDA IND获批，苏桥助力2000L GMP生产]]></content:encoded><pubDate>Mon, 01 Mar 2021 17:12:48 +0800</pubDate></item><item><title>百花齐放！常见双特异性抗体技术平台</title><link>https://mp.weixin.qq.com/s/nPIdl0-0FASlqh_LYXoAhA</link><description></description><content:encoded><![CDATA[百花齐放！常见双特异性抗体技术平台]]></content:encoded><pubDate>Sat, 27 Feb 2021 22:22:03 +0800</pubDate></item><item><title>4-1BB+T细胞：免疫治疗革命的主角</title><link>https://mp.weixin.qq.com/s/D4pDhkRvytBPW3rH0NFBhw</link><description></description><content:encoded><![CDATA[4-1BB+T细胞：免疫治疗革命的主角]]></content:encoded><pubDate>Fri, 26 Feb 2021 17:56:16 +0800</pubDate></item><item><title>新江湖｜医普科诺加入BiG会员机构！</title><link>https://mp.weixin.qq.com/s/mFMUuGfa3Xmx5TbjLtmHMw</link><description></description><content:encoded><![CDATA[新江湖｜医普科诺加入BiG会员机构！]]></content:encoded><pubDate>Fri, 26 Feb 2021 17:56:16 +0800</pubDate></item></channel></rss>